Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: Comparison of different assays and correlation with clinical features

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 10, 2004, Pages 1143-1152

  Annese, V ^a   Piepoli, A ^a   Perri, F ^a   Lombardi, G ^a   Latiano, A ^a   Napolitano, G ^a   Corritore, G ^a   Vandewalle, P ^b   Poulain, D ^b   Colombel, J F ^b   Andriulli, A ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FUNGUS ANTIBODY; MANNAN; SACCHAROMYCES CEREVISIAE MANNAN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LILLE ASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SEROPREVALENCE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, FUNGAL; ANTIBODY SPECIFICITY; COLITIS, ULCERATIVE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MANNANS; MIDDLE AGED; SACCHAROMYCES CEREVISIAE;

EID: 10644258124     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02258.x     Document Type: Article

References (26)

1. Main J, Mc Kenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (baker's yeast) in Crohn's disease. Br Med J 1988; 297: 1105-6.
2. Mc Kenzie H, Main J, Pennington CR, et al. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 1990; 31: 536-8.
3. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996; 3: 219-26.
4. Quinton JF, Sendid B, Reunaux D, et al. Anti-Saccharomyces cerevisiae mannan combined with antineutrophil antibodies in IBD: prevalence and diagnostic role. Gut 1998; 42: 788-91.
5. Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998; 93: 1-5.
6. Seibold F, Stich O, Hufnagel R, et al. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scan J Gastroenterol 2001; 36: 196-201.
7. Sutton CL, Yang H, Li Z, et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and un-affected relatives of patients with Crohn's disease. Gut 2000; 46: 58-63.
8. Annese V, Andreoli A, Andriulli A, et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis. A GISC study. Am J Gastroenterol 2001; 96: 2407-12.
9. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-4.
10. Sostegni R, Daperno M, Ercole E, et al. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker? Dig Liver Dis 2001; 33: 755-61.
11. Giaffer MH, Clark A, Holdsworth CD. Antibody to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut 1992; 33: 10971-5.
12. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogenous subgroups with distinct clinical characteristics. Gut 2000; 47: 487-96.
13. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004; 53: 1117-22.
14. Koutroubakis IR, Petinak E, Mouzas I, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 449-54.
15. Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001; 120: 827-33.
16. Sandborn WJ, Loftus EV, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001; 7: 192-201.
17. Moore MM, Fabricatorian D, Selby WS. Assessment and relevance of enzyme-linked immunosorbent assay for antibodies to Saccharomyces cerevisiae in Australian patients with IBD. Intern Med J 2002; 32: 349-52.
18. Klebl FH, Bataille F, Hofstadter F, Herfarth H, Scholmerich J, Rogler G. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis 2004; 19: 319-24.
19. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
20. Lombardi G, Annese V, Piepoli A, et al. Antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Clinical role and review of the literature. Dis Colon Rectum 2000; 43: 999-1007.
21. Zweig MH, Campbell G. Receiver operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-77.
22. Greiner M, Sohr D, Gobel P. A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. J Immunol Methods 1995; 185: 123-32.
23. Cohen J. A coefficient of agreement for nominal scales. Educ Psychiatr Meas 1960; 20: 37-46.
24. Bland MJ, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995; 346: 1085-7.
25. Young M, Davies MJ, Bailey D, et al. Characterization of oligosaccharides from an antigenic mannan of Saccharomyces cerevisiae. Glycoconj J 1998; 15: 815-22.
26. Wells AD, McMillan I, Price AB. Natural history of indeterminate colitis. Br J Surg 1991; 78: 179-81.